Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-cash Items (2023 - 2025)

Historic Non-cash Items for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $190.7 million.

  • CG Oncology's Non-cash Items rose 2133.93% to $190.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.7 million, marking a year-over-year increase of 2133.93%. This contributed to the annual value of $108.2 million for FY2024, which is 16844.13% up from last year.
  • CG Oncology's Non-cash Items amounted to $190.7 million in Q3 2025, which was up 2133.93% from $106.8 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Non-cash Items peaked at $231.2 million during Q1 2024, and registered a low of $40.3 million during Q4 2023.
  • Moreover, its 3-year median value for Non-cash Items was $130.6 million (2024), whereas its average is $134.3 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first skyrocketed by 16844.13% in 2024, then tumbled by 6223.47% in 2025.
  • Over the past 3 years, CG Oncology's Non-cash Items (Quarter) stood at $40.3 million in 2023, then skyrocketed by 168.44% to $108.2 million in 2024, then surged by 76.35% to $190.7 million in 2025.
  • Its Non-cash Items was $190.7 million in Q3 2025, compared to $106.8 million in Q2 2025 and $87.3 million in Q1 2025.